Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
St. Peters, MO
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
St. Peters, MO
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Billings, MT
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Billings, MT
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Toms River, NJ
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Toms River, NJ
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Syracuse, NY
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Syracuse, NY
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
West Seneca, NY
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
West Seneca, NY
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Durham, NC
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Durham, NC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Winston Salem, NC
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Canton, OH
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Canton, OH
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dayton, OH
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Pittsburgh, PA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Charleston, SC
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Greer, SC
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Greer, SC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Simpsonville, SC
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Nashville, TN
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Amarillo, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Fort Worth, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Houston, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Houston, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Irving, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Irving, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Plano, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Plano, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
San Antonio, TX
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Salt Lake City, UT
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Fredericksburg, VA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Richmond, VA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Virginia Beach, VA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Menomonee Falls, WI
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Menomonee Falls, WI
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated:  11/19/2015
mi
from
Edmonton,
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
Status: Enrolling
Updated: 11/19/2015
mi
from
Edmonton,
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Bay Minette, AL
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Bay Minette, AL
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Huntsville, AL
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Huntsville, AL
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Goodyear, AZ
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Anaheim, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Concord, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Concord, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
La Jolla, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Lancaster, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Lancaster, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Long Beach, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Mission Hills, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
National City, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
National City, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
North Hollywood, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
North Hollywood, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Northridge, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Northridge, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Palm Springs, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
San Mateo, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
San Mateo, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Spring Valley, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Spring Valley, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tarzana, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tarzana, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tustin, CA
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tustin, CA
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Norwalk, CT
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Norwalk, CT
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Boynton Beach, FL
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Jacksonville, FL
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Melbourne, FL
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Melbourne, FL
Click here to add this to my saved trials
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated:  11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Miami, FL
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)
Status: Enrolling
Updated: 11/20/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Miami, FL
Click here to add this to my saved trials